Oncology compounds comprise about one-third of the development projects in the pharmaceutical and biotech industry. Since years Pierrel Research has appointed a  dedicated team of professionals experienced in designing, planning, conducting and analysing oncology clinical trials.

Pierrel Research offers experience in oncology-specific grading systems and expertise at every level of clinical operations, pharmacovigilance, data management and biostatistics
We have worked for a great number of pharmaceutical and biotechnology companies worldwide as well as for national and international cancer working groups.

Therapeutic Indications

We have performed a remarkable number of clinical trials with  traditional cytotoxic chemotherapies as well as radiotherapy in :

  • Acute Myeloid Leukemia
  • Biliary Tract Cancer
  • Bone Cancer
  • Breast Cancer
  • Cervical Cancer
  • CIV infection
  • Colorectal Cancer
  • Cutaneous T Cell Lymphoma
  • GI stromal tumor
  • Liver Cancer
  • Lung Cancer
  • Malignant ascites
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Renal cell carcinoma
  • Skin cancer

Competitive advantages

  • Internal medical expertise
  • Fast and competitive study start-up
  • Dedicated Project Management
  • Preparation and distribution of Oncology IMPs
  • Greater skill sets and experience for clinical trial monitoring
  • Appropriate enrolling procedures and QC
  • Productive relationships with clinical research staff
  • Wide technology use for data qualification
  • Standardized training programs for CRAs

HyperSuite®: a Benefit for Oncology Trials

Pierrel Research Integrated Clinical Research Suite (HyperSuite®) allows the optimal conduct of oncology studies. HyperSuite MTP has excellent responsiveness and the speed needed to perform complex edit checks on the data collection forms. Flexibility, change control and validation are assured with the objective to handle adaptive study designs as a result of emerging data.  This may include additional cohorts, changes in study size, additional visits or trial extensions and study drug resupply. Our Integrated Web-Based Randomization and Drug Supply (IWRDS) module, directly linked to the study database, assures easy and correct patient randomization and a timely drug resupply.

Why HyperSuite® for Oncology

  • More timely safety reporting
  • Better tracking of concurrent medications
  • Enhanced oversight of study logistics
  • Specific indicator lesion accounting
  • Integrated image data
  • Adaptive design
  • Real-time event notification

HyperSuite® benefits

  • Dynamic site management
  • Transparency
  • Centralized study randomization
  • Effective trial drug supply management
  • Dynamic program management
  • Better planning
  • Better planned and less frequent site visits
  • Patient reported outcome integrated
  • Shared documents file
  • Continuous collaboration and communication
  • Real time safety collection and evaluation
  • Fast fail decisions
Flyer Onco-Immunology Research